logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Spain launched 44 clinical trials for cardiovascular diseases in 2020

Pharmacological treatments, together with heart-healthy lifestyles, are the factors that contribute the most to improving the control of these pathologies

The pharmaceutical industry has 600 investigational drugs in the world in this area alone

For every euro invested in antihypertensive drugs, 1.9 euros are saved in direct healthcare costs

This Sunday is the European Day for the Prevention of Cardiovascular Risk

Source: www.farmaindustria.es

 

Diseases of the circulatory system remain the leading cause of death worldwide, with approximately 17.5 million people dying from these diseases each year. According to the latest data provided by the National Institute of Statistics (INE), in the first five months of 2020 23% of deaths in our country were due to some pathology related to this area, even ahead of those caused by Covid -19 in the year marked by the pandemic.

But while the numbers are still very worrying, there is reason for hope. Pharmacological treatments and preventive measures, such as heart-healthy lifestyles, are helping to gradually reduce these mortality rates and improving the control of these diseases.

Not even the coronavirus has been able to stop this commitment of the pharmaceutical industry to the investigation of new cardiovascular treatments, as shown by data from the Spanish Registry of Clinical Studies (REEC), coordinated by the Spanish Agency for Medicines and Health Products (Aemps). Last year alone, 44 new clinical trials for heart disease were launched, making it the fifth most productive area.

In this sense, the research and development of new drugs for cardiovascular diseases is advancing in a triple direction: monoclonal antibodies with lipid-lowering action, enzyme inhibitors for the treatment of heart failure, and gene therapy aimed at reactivating the telomerase gene and regeneration of cardiomyocytes in patients who have suffered a myocardial infarction.

These lines of work are some of those that are being followed for the development of the almost 600 medications for the cardiovascular area that exist around the world. Not surprisingly, many have been those who have previously proven their value and have allowed cardiologists to change the course of many pathologies and the health system to register better health results and significant savings. In fact, a good part of the cardiovascular therapeutic arsenal are mature drugs – off-patent and with years of clinical experience – that represent a low cost for the National Health System and that continue to give the expected results.

The use of antihypertensive drugs, a cost-effective weapon

Thus, the main therapeutic option for these patients, in addition to correcting certain habits towards a healthy lifestyle, consists of the pharmacological treatment of high blood pressure and hypercholesterolemia. The SHEP (Systolic Hypertension in the Elderly Program) study concludes that antihypertensive treatment for 4.5 years prevents one in every 2 admissions for heart failure, one in every 3 heart attacks (fatal and non-fatal) and one in every 4 events cardiovascular It is estimated that each month of active antihypertensive treatment is associated with an increase of approximately one day in life expectancy.

In addition, it is estimated that the use of antihypertensive drugs during the 1990s in the United States avoided at the beginning of this new century a direct healthcare cost of $ 16.5 billion for myocardial infarction and stroke, 70% of which correspond to costs hospitable. It has been calculated that for every euro invested in antihypertensive drugs, 1.9 euros (almost 200%) are saved in direct healthcare costs.

This Sunday, March 14, is celebrated, as every year in Europe, the Day for the Prevention of Cardiovascular Risk, with the aim of drawing attention to the importance of cardiovascular diseases in society and, above all, to insist on the ability of each person to influence the main risk factors involved in most of these diseases, which are smoking, increased cholesterol, hypertension, uncontrolled diabetes, obesity and sedentary lifestyle.

 

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.